glp-1 drugs kidney disease agonists in the treatment of chronic in type 2 diabetes and obesity Potential kidney-protective and other effects

Preventive Services Task Force recommends that most people get a colorectal screening at least once every 10 years, now starting at age 45 years, to check for signs of colon cancer

Another potential concern some individuals have noted is a change in facial appearance, often called 'Ozempic face.' This isn't caused by the medication itself but rather by the rapid weight loss that can occur

Clinical evidence Evidence among individuals with diabetes Major cardiovascular outcome trials of GLP-1 RAs in individuals with T2DM have consistently demonstrated modest reductions in SBP (Table 1)

Nutrafol is another thing that people take, she says

Two large, randomized control trials investigating liraglutide and semaglutide have suggested worsening retinopathy as an adverse effect of GLP-1RA use

N Engl J Med 2009;361:2019-32.PubMed 12